Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

The first Integrated m-Health solution for anaphylaxis management.

Objetivo

Adan Medical Innovation is a private company focused on the medical devices and the m-health solutions markets. We have patented an m-Health technology for anaphylaxis management, which consists on a smart case for an epinephrine auto-injector linked via Bluetooth to a medical mobile app. Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death. The only adequate treatment is an immediate intramuscular epinephrine injection by using an auto-injector. However, patient self-management of auto-injectors has several problems: a) Need to check periodically drug condition, b) low adherence because patients forget carrying the auto-injector, c) difficulties to administer intramuscular epinephrine.
Adanmi has developed the first integrated solution to solve all these issues: a) The smart auto-injector case monitors epinephrine condition; b) The smartphone alerts distance from auto-injector in case the subject forgets it, c) during anaphylaxis it initiates an automated emergency protocol alerting contacts with exact GPS location and providing administration video-instructions.

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Régimen de financiación

SME-1 - SME instrument phase 1

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) H2020-SMEInst-2016-2017

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

ADAN MEDICAL INNOVATION SL
Aportación neta de la UEn
€ 50 000,00
Dirección
ANGLI 31 4 1
08017 BARCELONA
España
Pyme
Sí
Región
Este Cataluña Barcelona
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 71 429,00